	US 12,263,143 B2
	Ionic channel modulation as a method for treating tumors through inflammasome activation
Marcelo Hill Mongabure, Canelones (UY); Sofia Russo Rossi, Montevideo (UY); Mercedes Segovia Duarte, Canelones (UY); María Inés Varela Vega, Montevideo (UY); and Pablo Oppezzo Llorens, Canelones (UY)
Assigned to Institut Pasteur de Montevideo, Montevideo (UY); and University of the Republic, Montevideo (UY)
Filed by Institut Pasteur de Montevideo, Montevideo (UY); and University of the Republic, Montevideo (UY)
Filed on Oct. 28, 2021, as Appl. No. 17/513,232.
Application 17/513,232 is a continuation in part of application No. PCT/IL2020/050475, filed on Apr. 28, 2020.
Claims priority of provisional application 62/839,693, filed on Apr. 28, 2019.
Prior Publication US 2022/0184004 A1, Jun. 16, 2022
Int. Cl. A61K 31/138 (2006.01); A61K 31/166 (2006.01); A61K 31/167 (2006.01); A61K 31/4166 (2006.01); A61K 31/496 (2006.01); A61K 31/55 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)

CPC A61K 31/138 (2013.01) [A61K 31/166 (2013.01); A61K 31/167 (2013.01); A61K 31/4166 (2013.01); A61K 31/496 (2013.01); A61K 31/55 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01)]

2 Claims

1. A composition of use as a second therapeutic agent, to improve the efficacy of a first therapeutic agent which is an immune checkpoint blocker, wherein said composition is configured to trigger inflammasome activation and to inhibit TORID-dependent ion fluxes; further wherein said composition is selected from a group consisting of Aconitine, Lidocaine, Procainamide, Propafenone and any combination thereof.